Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesTA-MUC1 epitope in non-small cell lung cancer
Lung Cancer, 07/03/08
Kuemmel A et al. - In a study to determine the clinical relevance of carbohydrate-induced conformational tumor-associated MUC1 epitope (TA-MUC1) in lung cancer, it seems that the presence of TA-MUC1 is a favorable prognostic factor in this cohort of NSCLC pts, in particular if lymph node metastases are present
Methods- 85 paraffin-embedded tissue sections of NSCLC pts were stained with the monoclonal antibody PankoMab (against TA-MUC1) and compared with the established antibodies E29 and 214D4 regarding prognostic relevance
- TA-MUC1 is virtually absent in bronchial epithelium
- Only staining with PankoMab, but not with E29 or 214D4, was correlated with pts’ survival
- When regarding interactions of MUC1 antibody staining results and clinico-pathological parameters, pts with lymph node metastasis lacking PankoMab staining were attributed the highest risk
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Breast cancer in the elderly: a histological assessment
Histopathology, 10/15/09
Serum calcium levels are elevated among women with untreated postmenopausal breast cancer
Cancer Causes and Control, 11/03/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor
Sponsor